We are live on ! Find out more
BBA

Baker Bros. Advisors Portfolio holdings

AUM $17.4B
1-Year Est. Return 131.5%
This Fund
S&P 500
This Quarter Est. Return
-18.21%
1 Year Est. Return
+131.5%
3 Year Est. Return
+336.81%
5 Year Est. Return
+553.16%
10 Year Est. Return
+4,134.93%
AUM
$12.2B
AUM Growth
-$2.97B
Cap. Flow
+$24.4M
Cap. Flow %
0.2%
Top 10 Hldgs %
86.1%
Holding
101
New
4
Increased
12
Reduced
21
Closed
10

Top Buys

Rank Stock Value
1
ACAD icon
Acadia Pharmaceuticals
ACAD
+$219M
2
AMRN
Amarin Corp
AMRN
+$155M
3
KOD icon
Kodiak Sciences
KOD
+$81M
4
CMTA
Clementia Pharmaceuticals Inc.
CMTA
+$22.3M
5
KRYS icon
Krystal Biotech
KRYS
+$14M

Top Sells

Rank Stock Value
1
GHDX
Genomic Health, Inc.
GHDX
+$143M
2
SAGE
Sage Therapeutics
SAGE
+$80.2M
3
NVTA
Invitae Corporation
NVTA
+$58.3M
4
ECYT
Endocyte, Inc. Common Stock
ECYT
+$45.3M
5
LKFT
Lakefront Biotherapeutics American Depositary Shares
LKFT
+$21.5M

Sector Composition

Rank Sector Weight
1 Healthcare 92.2%
2 Technology 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ADMS
76
DELISTED
Adamas Pharmaceuticals
ADMS
$1.47M 0.01%
172,630
– –
GLMD icon
77
Galmed Pharmaceuticals
GLMD
$4.46M
$1.47M 0.01%
1,198
-603
-33% -$1.05M
LJPC
78
DELISTED
La Jolla Pharmaceutical Company
LJPC
$1.46M 0.01%
154,675
– –
ARAV
79
DELISTED
Aravive, Inc. Common Stock
ARAV
$1.42M 0.01%
404,384
-1
-0% -$6
RCUS icon
80
Arcus Biosciences
RCUS
$3.38B
$1.31M 0.01%
121,534
– –
MTEM
81
DELISTED
Molecular Templates, Inc.
MTEM
$1.03M 0.01%
16,949
– –
TRIL
82
DELISTED
Trillium Therapeutics Inc.
TRIL
$864K 0.01%
505,262
– –
DVAX
83
DELISTED
Dynavax Technologies
DVAX
$686K 0.01%
75,000
– –
INFI
84
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
$685K 0.01%
580,400
– –
TARA icon
85
Protara Therapeutics
TARA
$218M
$678K 0.01%
7,465
– –
AQST icon
86
Aquestive Therapeutics
AQST
$455M
$627K 0.01%
99,600
– –
AFMD
87
DELISTED
Affimed
AFMD
$622K 0.01%
20,000
– –
CNST
88
DELISTED
Constellation Pharmaceuticals, Inc.
CNST
$535K ﹤0.01%
133,333
– –
FLGT icon
89
Fulgent Genetics
FLGT
$566M
$396K ﹤0.01%
125,000
– –
VIRX
90
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$231K ﹤0.01%
15,905
– –
AIXC
91
AIxCrypto Holdings Inc
AIXC
$13.7M
$168K ﹤0.01%
22
– –
ARWR icon
92
Arrowhead Research
ARWR
$12.3B
– –
-307,496
Closed -$5.89M
OVID icon
93
Ovid Therapeutics
OVID
$431M
– –
-222,139
Closed -$1.26M
SAGE
94
DELISTED
Sage Therapeutics
SAGE
– –
-567,497
Closed -$80.2M
PHXM
95
DELISTED
PHAXIAM Therapeutics S.A.. American Depositary Shares
PHXM
– –
-108,597
Closed -$9.31M
MNTA
96
DELISTED
Momenta Pharmaceuticals, Inc.
MNTA
– –
-308,500
Closed -$8.11M
ECYT
97
DELISTED
Endocyte, Inc. Common Stock
ECYT
– –
-2,548,069
Closed -$45.3M
1 2 3
4

Similar funds

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
CM
Caption Management Oklahoma City, Oklahoma $17.1B AUM 70.99% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
ASRS
Arizona State Retirement System Phoenix, Arizona $17.1B AUM 30.52% 1-Year Est. Return
PP
Prudential plc London, England, United Kingdom $17.1B AUM 15.7% 1-Year Est. Return
VMPIC
Varma Mutual Pension Insurance Co Helsinki, Finland $17B AUM 24.09% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
BCIM
British Columbia Investment Management Victoria, British Columbia, Canada $17B AUM 31.69% 1-Year Est. Return

Baker Bros. Advisors's Q4 2018 Portfolio in Review

As of Q4 2018, Baker Bros. Advisors held 101 positions worth $12.2B, down 20% from $15.2B the previous quarter. Its ten largest holdings account for 86% of the portfolio.

Baker Bros. Advisors's Q4 2018 filing shows 4 new, 12 increased, 21 reduced and 10 closed positions. Its largest new stake was Kodiak Sciences: 9,145,115 shares worth $64.9M. The largest sale was Genomic Health, Inc., an estimated $143M.

By sector, the portfolio is most concentrated in Healthcare at 92% of assets, up from 91% a quarter earlier, followed by Technology.

  • Baker Bros. Advisors's largest Q4 2018 buy was Kodiak Sciences: 9,145,115 shares worth $64.9M.
  • Baker Bros. Advisors added most to Acadia Pharmaceuticals in Q4 2018, an estimated $219M increase.
  • Baker Bros. Advisors's biggest Q4 2018 reduction was Genomic Health, Inc., cutting an estimated $143M.
  • Baker Bros. Advisors fully exited Sage Therapeutics in Q4 2018, selling an estimated $80.2M.
  • Baker Bros. Advisors's ten largest holdings make up 86% of its $12.2B portfolio in Q4 2018.
  • Baker Bros. Advisors opened 4 new positions and closed 10 in Q4 2018.
  • Baker Bros. Advisors's portfolio value fell 20% quarter-over-quarter to $12.2B.

Based on Baker Bros. Advisors's 13F filing for Q4 2018, filed 13 Feb 2019.